References
Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, Page CD, Hansen RA. Mixed approach retrospective analysis of suicide and suicidal ideation for brand compared with generic central nervous system drugs. Drug Saf. 2018;41(4):363–76.
US FDA. Grant No. U01FD005272 “Post-market Authorized Generic Evaluation (PAGE)” awarded to Auburn University on 9 October 2014.
FDA Adverse Event Reporting System Public Dashboard. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Accessed 6 Apr 2018.
Iyer G, Marimuthu SP, Segal JB, Singh S. An algorithm to identify generic drugs in the FDA adverse event reporting system. Drug Saf. 2017;40(9):799–808.
Bohn J, Kortepeter C, Munoz M, Simms K, Montenegro S, Dal Pan G. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97(5):508–17.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035–43.
Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:2880.
McMillan KA, Enns MW, Asmundson GJ, Sareen J. The association between income and distress, mental disorders, and suicidal ideation and attempts: findings from the Collaborative Psychiatric Epidemiology Surveys. J Clin Psychiatry. 2010;71:1168–75.
Patrick AR, Miller M, Barber CW, et al. Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. Pharmacoepidemiol Drug Saf. 2010;19(12):1263–75.
Callahan ST, Fuchs DC, Shelton RC, et al. Identifying suicidal behavior among adolescents using administrative claims data. Pharmacoepidemiol Drug Saf. 2013;22(7):769–75.
Simon GE, Rutter CM, Peterson D, et al. Does response on the PHQ-9 depression questionnaire predict subsequent suicide attempt or suicide death? Psychiatr Serv. 2013;64(12):1195–202.
Anderson HD, Pace WD, Brandt E, et al. Monitoring suicidal patients in primary care using electronic health records. J Am Board Fam Med. 2015;28(1):65–71.
Stanley B, Currier GW, Chesin M, et al. Suicidal behavior and non-suicidal self-injury in emergency departments underestimated by administrative claims data. Crisis. 2017;19:1–8. https://doi.org/10.1027/0227-5910/a000499 (epub ahead of print).
Kim HM, Smith EG, Stano CM, Ganoczy D, Zivin K, Walters H, Valenstein M. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res. 2012;12:18.
Kristensen P. Bias from nondifferential but dependent misclassification of exposure and outcome. Epidemiology. 1992;3(3):210–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Courtney M. Suggs, Robert Levin, Andrew D. Mosholder, Richard S. Swain, and Liang Zhao have no conflicts of interest that are directly relevant to the content of this letter.
Funding
No sources of funding were used to assist in the preparation of this letter.
Additional information
This comment refers to the article available at https://doi.org/10.1007/s40264-017-0624-0.
An author’s reply to this comment is available at https://doi.org/10.1007/s40264-018-0728-1.
Rights and permissions
About this article
Cite this article
Suggs, C.M., Levin, R.L., Mosholder, A.D. et al. Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”. Drug Saf 41, 1419–1421 (2018). https://doi.org/10.1007/s40264-018-0726-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-018-0726-3